Merck KGaA’s earnings beat consensus on lab equipment, drug sales

This post was originally published on this site

https://i-invdn-com.investing.com/trkd-images/LYNXMPEIA9067_L.jpg

Third-quarter earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, rose 16.7% to 1.81 billion euros, surpassing the average estimate of 1.78 billion euros in an analyst poll on the company’s website.

The diversified group narrowed its full-year target range for adjusted EBITDA to between 6.80 billion and 7.20 billion euros, where it had previously forecast 6.75 billion to 7.25 billion.